Member Info for Fredd1eboy

My missus wonders if its announcing a large order before there is enough available stock to service it....Could this be the answer....thoughts anyone?

....So many very large trades are reported anywhere between an hour or more after the impact of the trade appears on L2.....It happens so often after its effect on the colour of the screen denotes the impact of the trade on the sp.....thoughts anyone?....is it just naive mm's taking us for mugs or a logical techy reason. Incidentally, it doesn't worry me....I just find it tiresome

Albeit I cannot attend in person, I look forward to receiving Arrons presentation next Tuesday.

A well deserved 10/10 from me for maintaining focus on both new and existing investors.

Appols all...I was in the process of tidying up the last post but accidentally pressed send. I failed to elaborate on the scope of aptamers initiatives...We only need one of these biggies to move to market, then yet another gold strike ... Keep up the good work Aptamer and up date us when you are ready, I have plenty of patience.

In a growing $21 billion market, our partner Unilever is by far the leader, but still has to conquer the foulest smelling odours. To date successful human skin sample trials have led to entire body inhuman trials in support of Unilevers new generation of deodorants.

Im guessing trials are well underway and I look forward to a progress update.

I have to remind myself of the work going on behind the scenes at Aptamer. Any one of the several initatives being driven by their executives will surely deliver gold for us all. Its just a matter of time and I've plenty of patience together with a significant growing investment. We'll done David....

Inspiring week in China for our CSO, David Bunka: CIFIT in Xiamen + visits to Wuxi, Hefei, Nanjing & Shanghai. 🤝

From meeting pharma & biotech leaders to exploring collaborations, the conversations sparked exciting future possibilities. 🙏 Thanks to our hosts & the FCDO!

...Cut and pasting the following two articles.....but success at just this one of Aptamers portfolio could propel our sp to dizzy heights....Its coming....don't lose heart as I'm convinced its coming

Baroness Susan Greenfield CBE, neuroscientist and founder of Neuro-Bio, has spent four decades pursuing a novel hypothesis about the origins of Alzheimer’s disease. Now, in collaboration with Aptamer Group, her team is developing a first-of-its-kind diagnostic test based on a unique biomarker. Leveraging Aptamer Group’s Optimer binders, the team aims to deliver an inexpensive, non-invasive screening tool that could identify Alzheimer’s up to 20 years before symptoms appear. If successful, this breakthrough could not only transform early detection but also open the door to preventative treatments, potentially making Alzheimer’s a preventable condition.

We mustn't lose focus on both the variety and depth of our portfolio....eg Success at just this one test alone could be a game changer for so many millions of Alzheimer's victims together with...their loved ones.

The team at Neuro-Bio had tried custom antibodies in the development of an Alzheimer's disease diagnostic, but couldn't get the sensitivity they needed for their novel biomarker.

Turning to Optimers provided the breakthrough they were after.

Read the interview to see how this potentially game-changing test might detect Alzheimer's decades before symptoms appear

Good for you Nok....well done

I should be pp...out now!

Looks like we won't have too long to wait as I appreciated being reminded....

(shortly reaching end Q1). We'll announce any further deals, as and when any contracts are signed, separately, if they meet the materiability test, in addition to any other relevant commercial updates.

As Ive previously mentioned that timing and £'s would be appreciated I contacted Adam earlier today and asked if there is any news I could share on LSE, clearly it was not of a sensitive nature but still encouraging as Adam kindly replied as follows....

Hi Fred. The lab is busy; we don't release all contracts as news now, as our market cap is higher, so the weight of "materiality" changes for RNSs, but we will release a Q1 statement which will outline the revenue of work in the lab from the last Q4, which is now bringing revenue in, plus the total contract values for Q1, which have been brought in since, when we've reached that end (shortly reaching end Q1). We'll announce any further deals, as and when any contracts are signed, separately, if they meet the materiability test, in addition to any other relevant commercial updates.

Too true...."dont take too many paractetamol".....What a plonker....I'd laugh if he wasn't so powerful....

Hi Guys. I appreciate your comments but I genuinely have 100% faith in Aptamers management and its science....I just enjoy it on this site. Guess Im spending too much time on the sofa. I'll get myself out tomorrow. Best regards Freddie

....an RNS which quantifies and qualifies the value of contracts / timing..... .Feeling, not too far off.....but hey, what do I know.....Its a gut feeling but my gut never lets me down.....DYOR newbies....

Https://aptamergroup.com/new-biomarkers-in-cancer-case-study/

Chunky early morning sells now being reported.....Wish they were declared at the time the trade was completed...St least we would know where we stand.....perhaps I'm asking too much of this dodgy aim market

... during Trumps presidency as I'm sure he would confuse Aptamers with staplers......What a plonker and if he really is the most powerful man on earth... God help us....

Personally I was pleasantly surprised to read the Chinese link...I hope we get into bed with them and at least rebalance status quo....

Clearing the decks.....bloody good riddance.....Aptamers looking a better buy by the minute.....Thank goodness Arron and the bod have held back releasing further value added news as it would have been lost in this quagmire....